Dermata Therapeutics (DRMA) Expected to Release Earnings on Wednesday

Dermata Therapeutics (NASDAQ:DRMA) will likely be issuing its Q3 2026 results on Wednesday, November 18th. Analysts expect Dermata Therapeutics to post earnings of ($0.55) per share and revenue of $0.03 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 7:00 AM ET.

Dermata Therapeutics (NASDAQ:DRMA) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.55) EPS for the quarter, meeting the consensus estimate of ($0.55). The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.03 million.

Dermata Therapeutics Price Performance

Shares of DRMA stock opened at $0.71 on Wednesday. Dermata Therapeutics has a 52-week low of $0.60 and a 52-week high of $4.66. The business has a 50-day simple moving average of $1.00 and a 200-day simple moving average of $1.27.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dermata Therapeutics in a report on Monday, October 26th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has an average rating of “Sell”.

About Dermata Therapeutics

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for dermatological diseases. The company’s research is centered on topical therapies intended to address common inflammatory and dermatologic conditions. Its lead product candidate, DMT310, is a once-weekly topical treatment being evaluated for conditions including psoriasis and acne vulgaris. The therapy is based on a proprietary platform derived from a naturally occurring freshwater sponge and is designed to deliver localized treatment to the skin.